Advertisement

European Journal of Clinical Pharmacology

, Volume 74, Issue 9, pp 1185–1186 | Cite as

Prevalence of use of antipsychotic drugs in the elderly in Catalonia

  • Carmen Asensio
  • Núria Escoda
  • Mònica Sabaté
  • Pere Carbonell
  • Pilar López
  • Joan-Ramon Laporte
Letter to the Editor

Montastruc et al. [1] reported an annual prevalence of use of antipsychotic drugs (APs) of 2.0% in the general population and 3.6% among those ≥ 65 years old in France.

The use of AP in the elderly is of concern. Systematic reviews by regulatory agencies [2, 3] have concluded that the use of APs for the treatment of aggression and psychotic symptoms in elderly patients with dementia increases mortality by twofold. In 2008, the European national regulatory agencies recommended limiting the use of APs to patients not responding to other interventions during the shortest possible period and to reconsider their prescription at every follow-up visit, with close patient follow-up [4].

In spite of these recommendations, in Catalonia between 2008 and 2013, the consumption by the general population of AP increased from 9.8 to 11.9 defined daily doses (DDD) per 1000 inhabitants and per day [5].

We examined the use of APs among the elderly in the Catalan Health Service (CHS) prescription claims...

References

  1. 1.
    Montastruc F, Bérnard-Laribière A, Noize P et al (2018) Antipsychotics use: 2006–2013 trends in prevalence and incidence and characterization of users. Eur J Clin Pharmacol 74:619–626CrossRefPubMedGoogle Scholar
  2. 2.
    US FDA (2005) http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/drugsafetyinformationforhealthcareprofessionals/publishealthadvisories/ucm053171.htm The document has been removed from the FDA website. The systematic review is described in: Schneider LS, Dagerman K, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294:1934–43
  3. 3.
  4. 4.
    AEMPS (2008) Antipsicóticos clásicos y aumento de mortalidad en pacientes ancianos con demencia Nota Informativa Ref 2008/19. http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2008/docs/NI_2008-19_antipsicoticos.pdf
  5. 5.
    Butlletí Groc (2017) Antipsicóticos: mala ciencia, pseudoinnovación, prescripción desbordada y yatrogenia 29:9–18. https://www.icf.uab.cat/assets/pdf/productes/bg/es/bg293-4.16e.pdf
  6. 6.
    Gilabert-Perramon A, López-Calahorra P, Escoda-Geli N, Salvadó-Trias C (2010) Receta electrónica en Cataluña (Rec@t): una herramienta de salud. Med Clin 134(Suppl 1):49–55CrossRefGoogle Scholar
  7. 7.
    Kaye JA, Bradbury BD, Jick H (2003) Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. Br J Clin Pharmacol 56:569–575CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Moore TJ, Mattison DR (2017) Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med 177:274–275CrossRefPubMedGoogle Scholar
  9. 9.
    Marston L, Nazareth I, Petersen I, Walters K, Osborn DPJ (2014) Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open 4:e006135CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Mirandola M, Andretta M, Corbari L, Sorio A, Nosè M, Barbui C (2006) Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999–2002. Pharmacoepidemiol Drug Saf 15:412–420CrossRefPubMedGoogle Scholar
  11. 11.
    Schmedt N, Jobski K, Kollhorst B, Krappweis J, Rüther E, Schink T, Garbe E (2016) Treatment patterns and characteristics of older antipsychotic users in Germany. Int Clin Psychopharmacol 31:159–169CrossRefPubMedGoogle Scholar
  12. 12.
    Oteri A, Mazzaglia G, Pecchioli S, Molokhia M, Ulrichsen SP, Pedersen L, Poluzzi E, de Ponti F, Garbe E, Schink T, Herings R, Bezemer ID, Sturkenboom MCJM, Trifirò G (2016) Prescribing pattern of antipsychotic drugs during the years 1996–2010: a population-based database study in Europe with a focus on torsadogenic drugs. Br J Clin Pharmacol 82:487–497CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA, CATIE-AD Study Group (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 355:1525–1538CrossRefPubMedGoogle Scholar
  14. 14.
    Gjerden P, Bramness JG, Tvete IF, Slørdal L (2017) The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004–2015. Eur J Clin Pharmacol 73:1173–1179CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Fundació Institut Català de Farmacologia, WHO Collaborating Centre for Research & Training in PharmacoepidemiologyUniversitat Autònoma de Barcelona, HU Vall d’HebronBarcelonaSpain
  2. 2.Gerència de Farmàcia i del Medicament, Servei Català de la SalutBarcelonaSpain
  3. 3.Servei de Farmacologia ClínicaHU Vall d’HebronBarcelonaSpain

Personalised recommendations